About PaQ

Introduction to PaQ®

PaQ is a three day insulin delivery device developed specifically for people with type 2 diabetes. The device is small and discreet proving both constant basal (background) insulin and bolus (mealtime) insulin. PaQ enables a life free from the burden of daily insulin injections.

PaQ has two components:

Infuser Unit

Continuous basal insulin

Push button bolus insulin

3 day use

Messenger Unit

Notification when to replace device and time of use

1 year use

How to Use PaQ®

PaQ® Facts

Developed specifically for people with type 2 diabetes

Up to 3 days of continuous subcutaneous insulin delivery

Worn on the abdomen

Small, ergonomic design

Be active, sleep, eat, exercise

Bathe, shower, swim (depth up to 6 ft)

Utilizes U100 rapid-acting insulin

7 preset basal doses

2 bolus units delivered with each button push

Delivers up to 330 units over 3 days

PaQ® Clinical Results

A recently completed clinical study evaluated the ability of people with Type 2 diabetes to use simple insulin infusion with the PaQ insulin delivery device to replace multiple daily injections. Study endpoints included glycemic control, patient satisfaction and safety. The only change from the baseline period of multiple daily injections and PaQ treatment was using the device to deliver insulin. Click here to view the study.

PaQ is Simple to Train, Use and Transition

With only one hour of training all participants were able to easily assemble and use PaQ without user errors.

All study participants were "very satisfied" (83%) or "satisfied" (17%) with the time it took to learn how to use PaQ and to administer bolus doses with PaQ

Transition was done simply and safely with 75% of the trial participants transitioning to PaQ with the first basal rate selected.

PaQ Effectively and Safely Delivers Basal and Bolus Insulin

Total daily insulin dose was similar on PaQ to baseline MDI therapy

Half the participants were able to reduce their insulin usage by more than 10% while on PaQ

PaQ was well tolerated

Hypoglycemia throughout the study was comparable to MDI, with fewer participants having hypo during the PaQ treatment period

Additional data being released at the ADA 73rd Scientific Sessions being held in Chicago.

PaQ Delivers Freedom From Daily Injections

Study participants found the device to be less embarrassing, less of a burden and less painful than current insulin injection treatments.

Additional data being released at American Diabetes Association 73rd Scientific Sessions.